Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

121. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia

Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Jukic V, Jakovljevic M, Filipcic I, Herceg M, Silic A, Tomljanovic T, Zilbershtein R, Jensen RC, Hemels ME, Einarson TR Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of long-acting injectable paliperidone palmitate for people with stable chronic schizophrenia and a history of relapse and hospitalisation. The authors concluded that paliperidone was the most cost-effective long-acting injectable atypical

NHS Economic Evaluation Database.2014

122. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial.

Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. 24508320 2014 04 24 2014 05 12 2016 11 22 1474-547X 383 9926 2014 Apr 19 Lancet (London, England) Lancet Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. 1395-403 10.1016/S0140-6736(13)62246-1 S0140-6736(13)62246-1 Antipsychotic drugs are usually the first line (...) of treatment for schizophrenia; however, many patients refuse or discontinue their pharmacological treatment. We aimed to establish whether cognitive therapy was effective in reducing psychiatric symptoms in people with schizophrenia spectrum disorders who had chosen not to take antipsychotic drugs. We did a single-blind randomised controlled trial at two UK centres between Feb 15, 2010, and May 30, 2013. Participants aged 16-65 years with schizophrenia spectrum disorders, who had chosen not to take

Lancet2014

123. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.

Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. IMPORTANCE: It is estimated that more than half of those with serious mental illness smoke tobacco regularly. Standard courses of pharmacotherapeutic cessation aids improve short-term abstinence, but most who attain abstinence relapse rapidly after discontinuation of pharmacotherapy. OBJECTIVE: To determine whether smokers diagnosed with schizophrenia (...) and bipolar disease have higher rates of prolonged tobacco abstinence with maintenance pharmacotherapy than with standard treatment. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, parallel-group, relapse-prevention clinical trial conducted in 10 community mental-health centers. Of 247 smokers with schizophrenia or bipolar disease recruited from March 2008-April 2012, 203 received 12-weeks' open-label varenicline and cognitive behavioral therapy and 87 met abstinence

JAMA2014 Full Text: Link to full Text with Trip Pro

124. Metformin for weight loss in schizophrenia: safe but not a panacea

Metformin for weight loss in schizophrenia: safe but not a panacea Metformin for weight loss in schizophrenia: safe but not a panacea | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin for weight loss in schizophrenia: safe but not a panacea Article Text Pharmacological interventions Metformin for weight loss in schizophrenia: safe but not a panacea Cenk Tek 1 , Lydia Chwastiak 2 Statistics from Altmetric.com No Altmetric data available for this article. What is already known on this topic? Obesity and diabetes rates are two to three times

Evidence-Based Mental Health2014

125. Case control study: People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition

Case control study: People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition Article Text Mental health Case control study People with schizophrenia are more likely to have a mother who smoked during

Evidence-Based Nursing (Requires free registration)2014

126. Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines

Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Long-term 5HT3 antagonist use (...) for schizophrenia: clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One systematic review and six randomized controlled trials were identified regarding the use of 5HT3 antagonists for the treatment of schizophrenia. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT3 Receptor Antagonistss Language Published English Country

Health Technology Assessment (HTA) Database.2014

128. Supported Employment for Schizophrenia

Supported Employment for Schizophrenia Supported Employment for Schizophrenia | Society of Clinical Psychology Supported Employment for Schizophrenia Status: Strong Research Support Description Supported Employment (SE; also known as Individual Placement and Support) is an approach to vocational rehabilitation (VR) adapted for individuals with serious mental illness. Supported employment emphasizes the integration of employment and mental health services, rapid placement of individuals (...) into jobs in the community, individualized job development, and ongoing job supports. Rather than segregating vocational rehabilitation and mental health services, supported employment specialists are part of the client’s treatment team. The goal of supported employment is to assist the person with schizophrenia in attaining competitive, community-based employment. As compared to more traditional VR approaches for this population (e.g. clubhouse models, transitional employment), the community-based

Society of Clinical Psychology2014

129. Social Skills Training for Schizophrenia

Social Skills Training for Schizophrenia Social Skills Training (SST) for Schizophrenia | Society of Clinical Psychology Social Skills Training (SST) for Schizophrenia Status: Strong Research Support Description SST uses the principles of behavior therapy to teach communication skills, assertiveness skills, and other skills related to disease management and independent living. SST is usually conducted in small groups that are ideally led by two co-therapists. Skills are broken down into several (...) on the needs of the client(s) and the treatment setting. SST may be even more helpful when supplemented with community-based practice opportunities and support. Key References (in reverse chronological order) Kopelowicz, A., Liberman, R.P., Zarate, R. (2006) Recent advances in social skills training for schizophrenia. Schizophrenia Bulletin, 32, pS12-S23. Bellack, AS (2002). Skills training for people with severe mental illness. Psychiatric Rehabilitation, 7, 375-391 Glynn, S.M., Marder, S.R., Liberman

Society of Clinical Psychology2014

130. Social Learning/Token Economy Programs for Schizophrenia

Social Learning/Token Economy Programs for Schizophrenia Social Learning/Token Economy Programs for Schizophrenia | Society of Clinical Psychology Social Learning/Token Economy Programs for Schizophrenia Status: Strong Research Support Description Token economy programs are generally used in long-term care setting such as long-stay inpatient units and residential care settings, but can be adapted for shorter stay and less intensive treatment programs as well. They are comprehensive behavioral (...) Services , 46(12): 1258-1263, 1995. Dickerson, F.D., Tenhula, W.N., & Green-Paden, L. (2005). The token economy for schizophrenia: Review of the literature and recommendations for future research. Schizophrenia Research . 75 (2-3): 405-416. Clinical Resources Ayllon, T., and Azrin, N.H. The Token Economy : A Motivational System for Therapy and Rehabilitation . Englewood Cliffs, NJ: Prentice Hall, 1968. Paul, G.L., and Lentz, R.J. Psychosocial Treatment of Chronic Mental Patients: Milieu versus Social

Society of Clinical Psychology2014

131. Illness Management and Recovery for Schizophrenia

Illness Management and Recovery for Schizophrenia Illness Management and Recovery (IMR) for Schizophrenia | Society of Clinical Psychology Illness Management and Recovery (IMR) for Schizophrenia Status: Modest Research Support Description Illness Management and Recovery (IMR) focuses on teaching illness self-management to persons with serious mental illness. The emphasis is on recovery by helping clients set and pursue personally meaningful goals. IMR combines 1) psychoeducation about mental (...) , development, and preliminary findings. Schizophrenia Bulletin, 32, p S32-S43. Gingerich, S. & Mueser, K.T. (2005). Illness management and recovery. In Drake, R.E., Merrens, M.R. & Lynde, D.E. (Eds). Evidence-based mental health practice: A textbook. New York, Norton. Clinical Resources Velligan, DI (2000). Cognitive Adaptation Training: The Use of Compensatory Strategies in the Psychosocial Rehabilitation of Patients with Schizophrenia. (Manual for therapists) UTHSCSA, Department of Psychiatry. Links

Society of Clinical Psychology2014

132. Cognitive Remediation for Schizophrenia

Cognitive Remediation for Schizophrenia Cognitive Remediation for Schizophrenia | Society of Clinical Psychology Cognitive Remediation for Schizophrenia Status: Strong Research Support Description Cognitive functions such as executive function, learning & memory, processing speed, and sustained attention are frequently impaired and play an important role in the functional impairments seen in schizophrenia. Cognitive remediation (CR) or cognitive rehabilitation interventions are designed (...) to improve cognitive function through repeated practice of cognitive tasks and / or strategy training. CR interventions are typically time-limited. They can be conducted individually or in groups. Some involve extensive use of computers while others focus primarily on paper-and-pencil tasks. Most CR interventions take into account the motivational and emotional deficits that are often present in schizophrenia as well. The goal of CR is to improve cognitive function. Research has shown small to medium

Society of Clinical Psychology2014

133. Cognitive Behavioral Therapy for Schizophrenia

Cognitive Behavioral Therapy for Schizophrenia Cognitive Behavioral Therapy (CBT) for Schizophrenia | Society of Clinical Psychology Cognitive Behavioral Therapy (CBT) for Schizophrenia Status: Strong Research Support Description Similar to Cognitive-Behavioral Therapy (CBT) for other types of problems, CBT for schizophrenia involves establishing a collaborative therapeutic relationship, developing a shared understanding of the problem, setting goals, and teaching the person techniques (...) or strategies to reduce or manage their symptoms. Therapy is usually conducted in individual sessions and is time-limited (typically several months). The goal is not to “cure” schizophrenia, but rather to improve the person’s ability to function independently, manage their schizophrenia, and to reduce the distress they experience in their daily life. Specific CBT approaches used in treating schizophrenia include cognitive restructuring, behavioral experiments / reality testing, self-monitoring and coping

Society of Clinical Psychology2014

134. Cognitive Adaptation Training for Schizophrenia

Cognitive Adaptation Training for Schizophrenia Cognitive Adaptation Training (CAT) for Schizophrenia | Society of Clinical Psychology Cognitive Adaptation Training (CAT) for Schizophrenia Status: Modest Research Support Description Cognitive Adaptation Training (CAT) is designed to improve everyday functioning by teaching the individual with schizophrenia to use strategies that compensate for (or work around) the cognitive deficits associated with schizophrenia. Treatment plans are based (...) place over several months and includes multiple visits to the client’s home and/or workplace. Key References (in reverse chronological order) Velligan , DI, Bow-Thomas, C.C., Huntzinger, C., Ledbetter, N., Prihoda, T.J., & Miller, A.L. (2000). Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. American Journal of Psychiatry, 157(8), 1317-1323. Velligan, D.I., Prihoda, T.J., Ritch, J.L., Maples, N., Bow-Thomas, C.C

Society of Clinical Psychology2014

135. Assertive Community Treatment for Schizophrenia

Assertive Community Treatment for Schizophrenia Assertive Community Treatment (ACT) for Schizophrenia | Society of Clinical Psychology Assertive Community Treatment (ACT) for Schizophrenia Status: Strong Research Support Description ACT is a multidisciplinary team approach to intensive case management in which the team members share a caseload, have a high frequency of patient contact (typically at least once a week), low patient to staff ratios, and provide outreach to patients (...) : the effect on hospital use and costs. Health Services Research , 34(2): 577-601, 1999. Lehman A.F.; Dixon L.B.; Kernan E.; DeForge B.R.; Postrado L.T. A randomized trial of assertive community treatment for homeless persons with severe mental illness. Archives of General Psychiatry , 54:1038-1043, 1997. Scott J.; Dixon L. Assertive community treatment and case management. Schizophrenia Bulletin 21(4):657-68, 1995. Burns B.J.; Santos, A.B. Assertive community treatment: an update of randomized trials

Society of Clinical Psychology2014

139. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. 24846035 2014 05 21 2014 06 02 2016 12 15 1538-3598 311 19 2014 May 21 JAMA JAMA Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. 1978-87 10.1001/jama.2014.4310 Long-acting injectable antipsychotics are used to reduce medication nonadherence and relapse in schizophrenia (...) diagnosed with schizophrenia or schizoaffective disorder who were clinically assessed to be at risk of relapse and likely to benefit from a long-acting injectable antipsychotic. Intramuscular injections of haloperidol decanoate 25 to 200 mg or paliperidone palmitate 39 to 234 mg every month for as long as 24 months. Efficacy failure, defined as a psychiatric hospitalization, a need for crisis stabilization, a substantial increase in frequency of outpatient visits, a clinician's decision that oral

JAMA2014 Full Text: Link to full Text with Trip Pro

140. Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial.

Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial. 24612754 2014 04 24 2014 05 12 2017 02 20 1474-547X 383 9926 2014 Apr 19 Lancet (London, England) Lancet Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial. 1385-94 10.1016/S0140-6736(13)62629-X S0140-6736(13)62629-X Observational evidence suggests (...) that community-based services for people with schizophrenia can be successfully provided by community health workers, when supervised by specialists, in low-income and middle-income countries. We did the COmmunity care for People with Schizophrenia in India (COPSI) trial to compare the effectiveness of a collaborative community-based care intervention with standard facility-based care. We did a multicentre, parallel-group, randomised controlled trial at three sites in India between Jan 1, 2009 and Dec 31

Lancet2014 Full Text: Link to full Text with Trip Pro